InnoCan Pharma Corporation (IP4.F)

0,1900 +0,0055 (+2,98%) Börsenschluss: 06:16PM CEST

InnoCan Pharma Corporation

1015, 926 – 5 Avenue SW
Calgary, AB T2P 0N7
Canada
403-777-1519
https://innocanpharma.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ron Mayron	Executive Chairman	126,78k	N/A	1963
Ms. Iris Bincovich	CEO & Director	314,14k	N/A	1970
Mr. Nelson Harvey Halpern F.C.A., FCPA	Chief Financial Officer	59,66k	N/A	1959
Mr. Roni Kamhi	COO & CEO of BI Sky Global	214,4k	N/A	1973
Mr. Eyal Flom L.L.M., M.B.A.	Director & Company Secretary	N/A	N/A	1967
Mr. Yoram Drucker	Founder & Executive VP of Business Development	161,27k	N/A	1965

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.

Corporate Governance

InnoCan Pharma Corporations ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.